Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Edward Favours
Observed names:
E Favours,
Edward G. Favours
Institution:
The University of Texas at San Antonio Health Science Center
Observed institutions:
St. Jude Children's Research Hospital,
Nationwide Children's Hospital,
Emory University,
The University of Texas at San Antonio Health Science Center,
Baylor College of Medicine
ORCID:
0009-0001-2023-2912
Observed ORCID:
0009-0001-2023-2912
OpenAlex ID:
A5141110200
The pediatric preclinical testing program: Description of models and early testing results
2006
·
Peter J. Houghton
, Christopher L. Morton
, et al.
·
Pediatric Blood & Cancer
·
510
Initial testing (stage 1) of tazemetostat (EPZ‐6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program
2016
·
Raushan T. Kurmasheva
, Melissa Sammons
, et al.
·
Pediatric Blood & Cancer
·
129
Evaluation of the Antitumor Efficacy, Pharmacokinetics, and Pharmacodynamics of the Histone Deacetylase Inhibitor Depsipeptide in Childhood Cancer Models In vivo
2006
·
Claire Graham
, Chandra Tucker
, et al.
·
Clinical Cancer Research
·
91
In vivo Evaluation of Ixabepilone (BMS247550), A Novel Epothilone B Derivative, against Pediatric Cancer Models
2005
·
Jennifer K. Peterson
, Chandra Tucker
, et al.
·
Clinical Cancer Research
·
86
Evaluation of ABT-751 against childhood cancer models in vivo
2007
·
Christopher L. Morton
, Edward G. Favours
, et al.
·
Investigational New Drugs
·
33
Evaluation of entinostat alone and in combination with standard‐of‐care cytotoxic agents against rhabdomyosarcoma xenograft models
2019
·
Raushan T. Kurmasheva
, Abhik Bandyopadhyay
, et al.
·
Pediatric Blood & Cancer
·
23
Evaluation of VTP‐50469, a menin‐MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium
2020
·
Raushan T. Kurmasheva
, Abhik Bandyopadhyay
, et al.
·
Pediatric Blood & Cancer
·
18
PDF
Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program
2010
·
Peter J. Houghton
, Christopher L. Morton
, et al.
·
Pediatric Blood & Cancer
·
12
Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models
2017
·
Abhik Bandyopadhyay
, Edward Favours
, et al.
·
Pediatric Blood & Cancer
·
11
Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
·
Clinical Cancer Research
·
3
Abstract P6-06-04: Targeting replication stress in triple negative breast cancer treatment regimen: An emerging approach
2018
·
S Rajamanickam
, JH Park
, et al.
·
Cancer Research
·
2
Abstract 7040: The B7-H3 targeting antibody-drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) is potently effective against a broad panel of pediatric solid tumor xenograft models: A study from the Pediatric Preclinical In Vivo Testing (PIVOT) Consortium
2025
·
Haiying Tang
, Edward Favours
, et al.
·
Cancer Research
·
1
Abstract 3100: Nanoformulated Talazoparib and Olaparib for enhanced delivery
2017
·
Paige Baldwin
, Rajiv Kumar
, et al.
·
Cancer Research
·
1
Abstract A137: Initial testing (Stage 1) of EPZ-6438 (tazemetostat), a novel EZH2 inhibitor, by the pediatric preclinical testing program (PPTP)
2015
·
Raushan Kurmasheva
, Kat Cosmopoulos
, et al.
·
Molecular Cancer Therapeutics
·
1
Supplementary Figure S2 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S1 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S5 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S5 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S7 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S10 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S9 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S6 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S9 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S8 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S1 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Show more works
View as search
Works count:
38
Citation count:
921
H-index:
9
I10-index:
9
Year
Topic
Type